- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
EXHIBIT 10.58
CONFIDENTIAL
December 11, 2006
Chris Penland, Ph.D.
Cystic Fibrosis Foundation Therapeutics, Inc.
6931 Arlington Road
Bethesda, MD 20814
Dear Dr. Penland:
The purpose of this letter (“Letter”) is to amend the Study Funding Agreement, between the undersigned parties, dated June 17, 2003, as amended (the “Agreement”). By signing below, the undersigned parties agree to the following:
In Section 8.1(c) of the Agreement,[ *] shall be replaced with[ *].
All other terms and provisions of the Agreement shall remain unchanged and are in full force and effect.
HOLLIS-EDEN PHARMACEUTICALS, INC. | ||||||||
By: | /s/ Eric J. Loumeau | Date: | December 11, 2006 | |||||
Eric J. Loumeau | ||||||||
Vice President, General Counsel |
Agreed to and Acknowledged by:
CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. | ||||||||
By: | /s/ Robert J. Beall | Date: | December 14, 2006 | |||||
Robert J. Beall, Ph.D. | ||||||||
President and CEO |
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.